NYSE:BIOA - Bioamber Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$0.0310
Today's Range$0.0120 - $0.0290
52-Week Range$0.0120 - $2.88
Volume15.51 million shs
Average Volume2.97 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

Receive BIOA News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Current RatioN/A
Quick RatioN/A


Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / BookN/A


Net IncomeN/A
Net MarginsN/A
Return on AssetsN/A


OptionableNot Optionable

Bioamber (NYSE:BIOA) Frequently Asked Questions

What is Bioamber's stock symbol?

Bioamber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."

How were Bioamber's earnings last quarter?

Bioamber Inc (NYSE:BIOA) posted its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.27) by $0.02. The biotechnology company earned $2.50 million during the quarter, compared to the consensus estimate of $2.37 million. View Bioamber's Earnings History.

What price target have analysts set for BIOA?

1 brokerages have issued 1-year target prices for Bioamber's shares. Their forecasts range from $1.75 to $1.75. On average, they expect Bioamber's share price to reach $1.75 in the next year. View Analyst Price Targets for Bioamber.

What is the consensus analysts' recommendation for Bioamber?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bioamber in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bioamber.

Has Bioamber been receiving favorable news coverage?

Media stories about BIOA stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bioamber earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near term.

Who are Bioamber's key executives?

Bioamber's management team includes the folowing people:
  • Raymond J. Land, Chairman of the Board (Age 72)
  • Richard P. Eno, Chief Financial Officer, Director
  • Mario Settino, Chief Financial Officer
  • Michael A. Hartmann, Executive Vice President (Age 48)
  • James Millis, Chief Technology Officer (Age 59)
  • Robert Frost, Director
  • Kurt W. Briner, Independent Director (Age 70)
  • Heinz Haller, Independent Director (Age 62)
  • Ellen B. Richstone, Independent Director (Age 65)
  • Kenneth W Wall, Independent Director (Age 66)

How do I buy shares of Bioamber?

Shares of BIOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bioamber's official website?

The official website for Bioamber is https://www.bio-amber.com/.

How can I contact Bioamber?

Bioamber's mailing address is 3850 Annapolis Ln N Ste 180, PLYMOUTH, MN 55447-5476, United States. The biotechnology company can be reached via phone at +1-612-7474423 or via email at [email protected]

MarketBeat Community Rating for Bioamber (NYSE BIOA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  151 (Vote Underperform)
Total Votes:  351
MarketBeat's community ratings are surveys of what our community members think about Bioamber and other stocks. Vote "Outperform" if you believe BIOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Featured Article: What is Liquidity?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel